A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease

NCT03521180 | Completed

• 2 other identifiers: NDS-CP-002U1111-1208-7879
• Study Type: observational
• Target: 5
• Locations: 1 country
• Sites: 2

Brief Summary

This is a model development, open label, no therapeutic treatment, three sequential group, short term-gluten challenge study in subjects with celiac disease. Immune responses are evaluated following gluten challenge. Approximately fifteen subjects with celiac disease will be enrolled in up to three sequential groups (5 subjects per group).

Conditions

Celiac Disease

Keywords

Celiac Disease; Gluten; Immune Response; Challenge

Outcome Measures

Primary Outcomes (3)

• Gut-homing, activated, CD8+ αβ T cells and γδ T cells in PBMC

  The number of gut-homing, activated, CD8+ αβ T cells and γδ T cells in PBMC will be reported separately by flow cytometry .

  Approximately 10 days

• Evaluation of Gliadin reactive T cell measures- PBMC (peripheral blood mononuclear cells) by Flow Cytometry

  Gliadin specific T cells will be evaluated by flow cytometry using fluorescently labelled HLA-gliadin tetramers that selectively bind to gliadin-specific T-cells.

  Approximately 10 days

• Gliadin reactive T cell measures- PBMC (peripheral blood mononuclear cells) by ELISPOT

  Gliadin specific T cells will be evaluated using Enzyme-linked immunospot (ELISPOT) which measure the number of cells secreting cytokine in response to gliadin binding.

  approximately 10 days

Study Arms (1)

Subjects with Celiac Disease

Group 1 will start the gluten challenge with 4 slices of white bread once daily for 3 days. Blood will be taken at pre-specified time points for up to 9 days following the start of gluten challenge for biomarker analyses. Based on data from the first 5 subjects, the 2nd group of 5 subjects may: 1) not be needed if the objectives are met; 2) receive gluten at increased quantity (not to exceed 6 slices of bread once daily for 3 days) or have biomarker samples collected at adjusted time points; 3) same as the first 5 subjects; 4) reducing the duration of gluten free diet for a minimum of 3 months instead of 6 month for the Inclusion Criteria # 5;5) subjects may be re-enrolled once. The same applies to the 3rd group of subjects. A notification will be provided to the clinical study site for detailed changes.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

A total of approximately 15 subjects (male or female) with celiac disease will be enrolled. Subjects must be positive for the HLA-DQ2.5+ haplotype. The disease should be well controlled through gluten-free diet. They must have followed a strict gluten free diet prior to screening with no symptoms that would suggest accidental gluten ingestion during that time.

You may qualify if:

• Subjects must satisfy the following criteria to be enrolled in the study:
• Male and female subjects of any race between 18 to 65 years of age (inclusive) at the time of signing the informed consent form (ICF).
• Must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
• Must be able to communicate with the investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
• Documented diagnosis of celiac disease ≥ 6 months before study entry, based on American College of Gastroenterology 2013 guideline on celiac disease diagnosis and management. The confirmation of a diagnosis of CD should be based on a combination of findings from the medical history, physical examination, serology, and upper endoscopy with histological analysis of multiple biopsies of the duodenum.
• A positive biopsy consistent with celiac disease. Every effort should be made to obtain the biopsy report to support the diagnosis of CD. Prospective subjects should not undergo biopsy for the sole purpose for participating in this trial. And
• A documented positive gluten-specific serology to tissue transglutaminase (tTG), endomysial antibodies (EMA), and/or gliadin-derived peptides (GDP).
• Group 1 subjects must have been following a gluten-free diet for ≥ 6 months before study entry and have been in remission based on self-reporting and must have negative IgA antibodies to tTG at screening. For Group 2 and 3 the gluten free diet duration may be reduced to a minimum of 3 months. Notification of the changes for Group 2 and 3 will be provided to the site(s).
• Subjects must have HLA DQ2.5 (i.e., DQA1\*05/DQB1\*02).
• No clinically significant abnormal laboratory test results other than those related to celiac disease as determined by the investigator.
• At the screening visit, must be afebrile, with supine systolic BP: 90 to 140 mmHg, supine diastolic BP: 50 to 90 mmHg, and pulse rate: 40 to 110 bpm. Eligibility criteria for vital signs performed on Day 0 (or Day 1 pre-gluten challenge) will be at the discretion of the Investigator. In the opinion of the Investigator, subjects with hypertension controlled with a concomitant medication will be allowed in the study.
• Must have a normal or clinically acceptable 12-lead ECG.
• Female subject must have a negative pregnancy test at screening and on Day 0 (or Day 1 pre-gluten challenge).
• Subject must be willing and able to adhere to the study visit schedule and other protocol requirements.

You may not qualify if:

• The presence of any of the following will exclude a subject from enrollment:
• Any significant medical condition, laboratory abnormality, or psychiatric illness, Type 1 diabetes, other than celiac disease, that would prevent the subject from participating in the study.
• Any condition which places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
• Use of any prescribed systemic immune modulator medication within 30 days of the first bread administration.
• The use of prescribed and over-the-counter non-steroidal anti-inflammatory drugs (NSAID) within 14 days of the first bread administration.
• Exposure to an investigational drug (new chemical entity) within 30 days prior to the first bread administration or 5 half-lives of that investigational drug, if known (whichever is longer).
• Donated blood or plasma within 8 weeks before the first bread administration to a blood bank or blood donation center.
• History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual \[DSM\]) within 2 years before dosing, or a positive drug screen reflecting consumption of illicit drugs. For states in which marijuana is legal; prior use of marijuana may be acceptable as long as the screening drug screen is negative. Subjects may be re-screened in case the drug screen tests positive for marijuana. Subjects must refrain from the use of marijuana 2 weeks prior to screening until the end of study.
• History of alcohol abuse (as defined by the current version of the DSM) within 2 years before screening, or a positive alcohol screen.
• Known to have hepatitis, or known to be a carrier of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab), or have a positive result to the test for human immunodeficiency virus (HIV) antibodies at screening.
• Any condition that confounds the ability to interpret data from the study.
• Subjects with a history of hypersensitivity or anaphylaxis to gluten.

Sponsors & Collaborators

• Celgene: lead

Study Sites (2)

Covance

Dallas, Texas, 75247, United States

Location

Virginia Mason Medical Center

Seattle, Washington, 98101, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

The ICF relates that biospecimens will be retained at the central laboratory or another secure storage facility. It does make it clear samples will be destroyed after 5 years. Or that subjects can withdraw and have their samples destroyed.

MeSH Terms

Conditions

Celiac Disease

Condition Hierarchy (Ancestors)

Malabsorption Syndromes; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Ying Ye, PhD

  Celgene

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2018
• First Posted: May 11, 2018
• Study Start: May 11, 2018
• Primary Completion: July 18, 2019
• Study Completion: July 18, 2019
• Last Updated: February 26, 2020

Record last verified: 2020-02

Locations

US (2)